IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 dose escalation/expansion trial ...
Pharmabiz

IDEAYA Biosciences begins patient enrolment in phase 1 trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC

IDEAYA Biosciences begins patient enrolment in phase 1 trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC: South San Francisco, California Friday, February 27, 2026 ...
The American Journal of Managed Care

Dr Timothy Yap: PARP/TOP1 Inhibitor Toxicities Can Be Managed Through Targeted Delivery

Targeted tumor delivery of irinotecan through sacituzumab govitecan can help to reduce treatment-related toxicities, noted Timothy A. Yap, MBBS, PhD, FRCP, medical director of the Institute for ...
ascopubs.org

Antitumor activity of indenoisoquinoline inhibitors of topoisomerase 1 (TOP1) via apoptosis and autophagocytosis pathways in animal models.

Impact and correlation of mutational load (ML) and specific mutations (mts) assessed by limited targeted profiling (LTP) with PD-L1 tumour expression (exp) in resected non-small cell lung carcinoma ...